S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Veracyte Stock Forecast, Price & News

+0.14 (+0.71%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
887,180 shs
Average Volume
958,105 shs
Market Capitalization
$1.43 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Stock Forecast (MarketRank)

Overall MarketRank

2.12 out of 5 stars

Medical Sector

475th out of 1,432 stocks

Medical Laboratories Industry

14th out of 32 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Veracyte logo

About Veracyte (NASDAQ:VCYT)

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$-75.56 million
Pretax Margin


Sales & Book Value

Annual Sales
$219.51 million
Book Value
$15.43 per share


Free Float
Market Cap
$1.43 billion

Veracyte Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Veracyte stock.
View analyst ratings for Veracyte
or view top-rated stocks.

What is Veracyte's stock price forecast for 2022?

7 brokers have issued 1 year target prices for Veracyte's stock. Their VCYT stock forecasts range from $26.00 to $59.00. On average, they expect Veracyte's share price to reach $42.14 in the next twelve months. This suggests a possible upside of 111.0% from the stock's current price.
View analysts' price targets for Veracyte
or view top-rated stocks among Wall Street analysts.

How has Veracyte's stock price performed in 2022?

Veracyte's stock was trading at $41.20 at the beginning of 2022. Since then, VCYT shares have decreased by 51.5% and is now trading at $19.97.
View the best growth stocks for 2022 here

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Veracyte

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. The biotechnology company earned $67.78 million during the quarter, compared to analyst estimates of $61.98 million. Veracyte had a negative trailing twelve-month return on equity of 4.09% and a negative net margin of 19.22%. During the same quarter in the previous year, the business posted ($0.11) earnings per share.
View Veracyte's earnings history

What guidance has Veracyte issued on next quarter's earnings?

Veracyte issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $265.00 million-$275.00 million, compared to the consensus revenue estimate of $270.30 million.

Who are Veracyte's key executives?

Veracyte's management team includes the following people:
  • Ms. Bonnie H. Anderson, Co-Founder & Exec. Chairwoman (Age 64, Pay $1.21M) (LinkedIn Profile)
  • Mr. Marc A. Stapley, CEO & Director (Age 52, Pay $900.4k)
  • Ms. Rebecca Chambers, Exec. VP & CFO (Age 44, Pay $607.65k)
  • Dr. Giulia C. Kennedy Ph.D., Global Chief Scientific Officer & Chief Medical Officer (Age 63, Pay $691.33k)
  • Dr. Tina S. Nova Ph.D., Pres of CLIA U.S. Bus. (Age 68, Pay $4.58k)
  • Ms. Beverly Jane Alley CPA, VP & Corp. Controller (Age 59, Pay $398.01k)
  • Mr. Jonathan Wygant, VP & Chief Accounting Officer (Age 51)
  • Mr. William W. Zondler, Sr. VP & Chief Information Officer
  • Ms. Annie McGuire, Sr. VP & Gen. Counsel (Age 42)
  • Ms. Tracy Morris, VP of Global Corp. Communications

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $19.97.

How much money does Veracyte make?

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.43 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75.56 million in net income (profit) each year or ($0.680010) on an earnings per share basis.

How many employees does Veracyte have?

Veracyte employs 761 workers across the globe.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for Veracyte is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at [email protected], or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.